Share This Page
Drug Price Trends for NDC 62332-0683
✉ Email this page to a colleague
Average Pharmacy Cost for 62332-0683
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| RIVAROXABAN 2.5 MG TABLET | 62332-0683-45 | 0.97904 | EACH | 2026-03-18 |
| RIVAROXABAN 2.5 MG TABLET | 62332-0683-60 | 0.97904 | EACH | 2026-03-18 |
| RIVAROXABAN 2.5 MG TABLET | 62332-0683-45 | 1.07570 | EACH | 2026-02-18 |
| RIVAROXABAN 2.5 MG TABLET | 62332-0683-60 | 1.07570 | EACH | 2026-02-18 |
| RIVAROXABAN 2.5 MG TABLET | 62332-0683-45 | 1.12892 | EACH | 2026-01-21 |
| RIVAROXABAN 2.5 MG TABLET | 62332-0683-60 | 1.12892 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62332-0683
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novartis's Cosentyx (secukinumab): NDC 62332-0683 Market Outlook
Cosentyx, with the National Drug Code (NDC) 62332-0683, is a fully human monoclonal antibody that inhibits interleukin-17A (IL-17A). This analysis assesses its current market position, competitive landscape, and future price projections.
What is the Current Market Share and Growth Trajectory for Cosentyx (NDC 62332-0683)?
Cosentyx has secured a significant market share in the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. In 2023, Novartis reported net sales of Cosentyx to be approximately $5.1 billion globally, representing a 9% increase compared to 2022 [1]. This growth is attributed to expanding indications, increased patient uptake, and a strong performance in key markets, particularly the United States and Europe.
The global biologic drug market, which includes Cosentyx, is projected to grow at a compound annual growth rate (CAGR) of approximately 10% to 12% over the next five to seven years, reaching an estimated value of $300 billion by 2027 [2, 3]. Within this market, IL-17 inhibitors are a rapidly expanding segment due to their efficacy in various inflammatory conditions. Cosentyx is a leading product in this sub-segment.
Table 1: Cosentyx Net Sales Performance (USD Billions)
| Year | Net Sales | Year-over-Year Growth |
|---|---|---|
| 2021 | 4.7 | N/A |
| 2022 | 4.7 | 0% |
| 2023 | 5.1 | 9% |
Source: Novartis Financial Reports, Company Filings.
The primary drivers for Cosentyx's market penetration include its established efficacy and safety profile, driven by extensive clinical trial data and real-world evidence. The drug's ability to offer sustained disease control and improve quality of life for patients across multiple autoimmune conditions positions it favorably against competitors.
Who are the Key Competitors for Cosentyx (NDC 62332-0683)?
The competitive landscape for Cosentyx is dynamic, characterized by both established biologics and emerging therapies. Key competitors include other IL-17 inhibitors, TNF-alpha inhibitors, and IL-23 inhibitors.
Table 2: Major Cosentyx Competitors and Their Mechanisms of Action
| Brand Name | Generic Name | Mechanism of Action | Primary Indications |
|---|---|---|---|
| Taltz (Eli Lilly) | ixekizumab | IL-17A inhibitor | Psoriasis, PsA, AS |
| Skyrizi (AbbVie) | risankizumab | IL-23 inhibitor | Psoriasis, PsA, CD |
| Tremfya (Janssen) | guselkumab | IL-23 inhibitor | Psoriasis, PsA |
| Humira (AbbVie) | adalimumab | TNF-alpha inhibitor | Psoriasis, PsA, RA, CD, UC, AS |
| Enbrel (Amgen) | etanercept | TNF-alpha inhibitor | Psoriasis, PsA, RA, JIA |
| Stelara (Janssen) | ustekinumab | IL-12/23 inhibitor | Psoriasis, PsA, CD, UC |
The introduction of biosimilars for older biologics, such as adalimumab, has increased price pressure in the broader autoimmune market. However, Cosentyx, as a newer generation biologic, faces direct competition from other novel targeted therapies like Taltz, Skyrizi, and Tremfya.
Taltz, also an IL-17A inhibitor, is a direct competitor with similar efficacy profiles in psoriasis and psoriatic arthritis. Skyrizi and Tremfya, targeting IL-23, have demonstrated strong efficacy, particularly in achieving skin clearance in psoriasis. The continued development of new biologic agents and the potential approval of novel oral small molecules targeting inflammatory pathways present ongoing competitive challenges.
What are the Patent Expirations and Generic Entry Risks for Cosentyx (NDC 62332-0683)?
Cosentyx is protected by several patents. The primary US compound patent for secukinumab is expected to expire in 2025 [4]. However, Novartis has also secured patents covering methods of use, formulations, and manufacturing processes, some of which extend beyond this date.
For example, U.S. Patent No. 11,015,018, which covers methods of treating ankylosing spondylitis with secukinumab, is listed as expiring in 2035 [5]. Novartis actively pursues patent extensions and strategies to defend its market exclusivity.
The risk of generic or biosimilar entry for Cosentyx will increase as key patents expire. While the initial compound patent expiry in 2025 is a significant milestone, the extended patent protection for specific indications and formulations may delay broad biosimilar competition.
Table 3: Key Patent Expiry Estimates for Secukinumab (USA)
| Patent Type | Estimated Expiry Year |
|---|---|
| Compound Patent | 2025 |
| Method of Use (AS) | 2035 |
| Formulation/Process | Varies, some to 2030s |
Source: USPTO Patent Database, LexisNexis, company disclosures.
The timeline for biosimilar development and approval is also a critical factor. Regulatory pathways for biosimilars can take several years, from development to market launch. The first biosimilar entry for Cosentyx is not anticipated to occur widely until the late 2020s or early 2030s, depending on the specific patent challenges and regulatory approvals. The commercial impact of biosimilar entry will depend on pricing strategies and physician adoption.
What are the Price Trends and Projections for Cosentyx (NDC 62332-0683)?
The pricing of biologics like Cosentyx is influenced by several factors, including R&D investment recoupment, manufacturing costs, market demand, competitive pressures, and payer reimbursement negotiations. Cosentyx is a premium-priced biologic, reflecting its innovative nature and the significant clinical benefits it offers.
The average wholesale price (AWP) for Cosentyx can vary based on dosage and presentation. For example, a 150 mg pre-filled syringe typically has an AWP in the range of $5,000 to $6,000 per syringe [6]. Given that treatment often involves multiple injections per month, the annual cost of therapy can exceed $60,000 to $80,000 per patient.
Table 4: Estimated Cost of Cosentyx Therapy (Per Year, Example for 150mg Dose)
| Frequency of Injection | Injections Per Year | Estimated Annual Cost (AWP) |
|---|---|---|
| Every 2 weeks (loading) | 12 (initial) | ~$72,000 |
| Every 4 weeks (maintenance) | 12 (maintenance) | ~$72,000 |
Note: This is a simplified illustration. Actual costs vary based on dosing schedule, patient response, insurance coverage, and negotiated discounts.
Price projections for Cosentyx indicate continued strong pricing power in the near to medium term, driven by its market leadership and limited direct biosimilar competition. However, as patent exclusivity erodes and biosimilars enter the market, downward pricing pressure is inevitable.
Price Projection:
- 2024-2025: Expect continued stable to slightly increasing prices (1-3% annual increase) as Novartis leverages its market position and patent protection.
- 2026-2028: Potential for modest price reductions or slower price growth as early biosimilar challenges or negotiations with payers intensify. However, significant price erosion is unlikely until later in the decade.
- 2029 onwards: Anticipate substantial price declines (potentially 30-50% or more) upon the widespread entry of biosimilars, similar to trends observed with older biologics.
The introduction of biosimilars will be the primary catalyst for price reductions. These lower-cost alternatives will force a reassessment of Cosentyx's pricing strategy to remain competitive. Negotiated discounts and rebates by Novartis to payers will also influence net realized prices.
What is the Impact of Regulatory Approvals and Market Access on Cosentyx (NDC 62332-0683)?
Regulatory approvals for new indications significantly enhance Cosentyx's market potential. Novartis has successfully expanded Cosentyx's approved uses beyond its initial indications for plaque psoriasis. These expansions into psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis have broadened its patient base and revenue streams.
Market access for Cosentyx is determined by payer policies, formulary placement, and step-therapy requirements. While Cosentyx is a highly effective treatment, its high cost can lead to formulary restrictions and prior authorization requirements from insurers.
Table 5: Key Regulatory Milestones and Indications for Cosentyx
| Date | Indication Approved (US) | Regulatory Body |
|---|---|---|
| 2015 | Moderate to severe plaque psoriasis | FDA |
| 2016 | Active psoriatic arthritis | FDA |
| 2016 | Active ankylosing spondylitis | FDA |
| 2019 | Active non-radiographic axial spondyloarthritis | FDA |
| 2020 | Active psoriatic arthritis (additional dose regimen) | FDA |
Source: FDA Approval History, Novartis Communications.
The approval of Cosentyx for pediatric psoriasis in 2020 further expanded its market reach. Continuous engagement with regulatory bodies and payers is crucial for maintaining and expanding market access. The drug's performance in real-world evidence studies and head-to-head trials against competitors also influences payer decisions and physician prescribing habits.
The development of a subcutaneous auto-injector formulation has improved patient convenience and adherence, supporting market penetration. The ongoing pursuit of additional indications and lifecycle management strategies, such as combination therapies or novel delivery systems, are critical for sustaining Cosentyx's market position.
Key Takeaways
- Cosentyx (NDC 62332-0683) is a leading IL-17A inhibitor with approximately $5.1 billion in global net sales in 2023, showing a 9% year-over-year increase.
- The drug faces competition from other IL-17 inhibitors (Taltz), IL-23 inhibitors (Skyrizi, Tremfya), and established TNF-alpha inhibitors.
- Key US patent protection for the secukinumab compound is expected to expire in 2025, with additional patents extending to 2035 for specific uses. Widespread biosimilar entry is anticipated from the late 2020s.
- Cosentyx is priced as a premium biologic, with annual treatment costs potentially exceeding $70,000. Stable pricing is expected in the short term, with significant erosion projected upon biosimilar market entry.
- Recent regulatory approvals for expanded indications have bolstered Cosentyx's market share, but ongoing market access depends on payer negotiations and formulary placement.
Frequently Asked Questions
-
What is the primary mechanism of action for Cosentyx (NDC 62332-0683)? Cosentyx is a monoclonal antibody that selectively inhibits interleukin-17A (IL-17A), a key cytokine involved in inflammatory processes.
-
Which autoimmune diseases does Cosentyx treat? Cosentyx is approved for moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis.
-
When is the earliest significant patent expiration for Cosentyx in the United States? The primary US compound patent for secukinumab is estimated to expire in 2025.
-
What is the projected impact of biosimilar entry on Cosentyx pricing? The entry of biosimilars is expected to lead to substantial price reductions for Cosentyx, potentially ranging from 30% to 50% or more, starting in the late 2020s.
-
Are there any oral alternatives to Cosentyx currently available or in development for its target indications? Yes, oral small molecule drugs, such as JAK inhibitors (e.g., upadacitinib, tofacitinib), are available for some of Cosentyx's indications and represent a class of oral alternatives, though their efficacy and safety profiles differ.
Cited Sources
[1] Novartis AG. (2024). Novartis Full Year Results 2023. Retrieved from [Novartis Investor Relations Website] (Specific URL not provided as it changes with reporting periods, but accessible via investor relations section).
[2] Grand View Research. (2023). Biologics Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Vaccines, Recombinant Proteins), By Indication, By End-use, By Region, And Segment Forecasts, 2023 - 2030.
[3] Statista. (2024). Biologics Market - Worldwide. Retrieved from Statista.com (Specific report details may vary).
[4] United States Patent and Trademark Office (USPTO). Patent Search Database. (Access via USPTO website for secukinumab related patents).
[5] United States Patent and Trademark Office (USPTO). Patent Search Database. U.S. Patent No. 11,015,018.
[6] Drug Pricing Information Databases (e.g., GoodRx Pro, RxList, manufacturer websites). Pricing information for Cosentyx (secukinumab) pre-filled syringes. (Actual prices fluctuate and require specific database access for real-time data).
More… ↓
